Last update 30 Nov 2024
KQ-2002
Last update 30 Nov 2024
Overview
Basic Info
Drug Type Autologous CAR-T |
Synonyms- |
Target |
Mechanism CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors), CD22 inhibitors(CD22 inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
2
Clinical Trials associated with KQ-2002A Preliminary Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetic Profile of KQ-2002 (CD19/CD22 CAR-T) in Adults With Recurrent or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma
Clinical study on the safety and effectiveness of targeting CD19 and CD22 CAR - T cells immunotherapy in patients with relapsed or refractory acute B lymphocytic leukemia
100 Clinical Results associated with KQ-2002
Login to view more data
100 Translational Medicine associated with KQ-2002
Login to view more data
100 Patents (Medical) associated with KQ-2002
Login to view more data
100 Deals associated with KQ-2002
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Acute lymphoblastic leukemia recurrent | Phase 1 | CN | 31 May 2024 | |
| B-cell lymphoma recurrent | Phase 1 | CN | 31 May 2024 | |
| B-cell lymphoma refractory | Phase 1 | CN | 31 May 2024 | |
| Refractory T Acute Lymphoblastic Leukemia | Phase 1 | CN | 31 May 2024 | |
| B-Cell Lymphoma | Phase 1 | - | - | |
| Recurrent B Acute Lymphoblastic Leukemia | IND Approval | CN | 25 Nov 2024 | |
| Refractory B Acute Lymphoblastic Leukemia | IND Approval | CN | 25 Nov 2024 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free